Individual Patient Compassionate Use of Mirdametinib
Sponsor: SpringWorks Therapeutics, Inc.
Expanded Access
Sponsor score: 60
Inactive
ClinicalTrials ID:NCT05028166
This compassionate use program provides oral mirdametinib to patients with serious, debilitating, or life-threatening conditions lacking satisfactory treatment options. Eligible patients must not qualify for ongoing clinical trials. Approval from the company, IRB/IEC, and relevant authorities is required for participation.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Eligibility Criteria
Inclusion Criteria
- Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.
- Patient does not qualify to participate in an ongoing clinical trial.
Get This Program In Your Inbox
You can sign up and apply your patients for this program.